Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Charles Yuan-Chia Kuo
Observed names:
Y Kuo,
Y. Kuo,
Yuan-Chia Kuo
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
University of Maryland, Baltimore,
Center for Biologics Evaluation and Research,
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
University of Maryland School of Medicine,
University of Maryland, College Park,
University of Pennsylvania
show all 7
ORCID:
0000-0002-3740-176X
Observed ORCID:
0000-0002-3740-176X
OpenAlex ID:
A5064301133
Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII
2009
·
Mathura P. Ramanathan
, Michele A. Kutzler
, et al.
·
Vaccine
·
54
Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes
2009
·
Mathura P. Ramanathan
, Yuan-Chia Kuo
, et al.
·
Vaccine
·
46
Colloidal Properties of Nanoerythrosomes Derived from Bovine Red Blood Cells
2015
·
Yuan-Chia Kuo
, Hsuan-Chen Wu
, et al.
·
Langmuir
·
40
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
·
Clinical Cancer Research
·
7
Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
2021
·
Peter Radvak
, Martina Kosikova
, et al.
·
npj Vaccines
·
5
PDF
Mapping the Antibody Repertoires in Ferrets with Repeated Influenza A/H3 Infections: Is Original Antigenic Sin Really “Sinful”?
2023
·
Tal Einav
, Martina Kosikova
, et al.
·
Viruses
·
3
PDF
Liposomal nanoprobes that combine anti-EGFR antibodies and MRI contrast agents: synthesis and in vitro characterization
2014
·
Yuan-Chia Kuo
, Chiwei Hung
, et al.
·
RSC Advances
·
2
Liposome-based Nanoprobe With Antibody Conjugation Combined With MRI Contrast Encapsulation as a Potential Diagnostic and Therapeutic Agent for Human Head-and-Neck Cancer Cells
2012
·
Y. Kuo
, C. Hung
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
1
Supplementary Table S6 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Data from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
Supplementary Table S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S5 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S7 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
TH‐C‐141‐02: Imaging of Targeted Cancer Therapy Using Multifunctional Liposomal Nanoprobes and MRI
2013
·
Y Kuo
, C Hung
, et al.
·
Medical Physics
TU‐G‐134‐04: Multifunctional Molecular Probes for Targeting and Imaging of Epidermal Growth Factor Receptors in Vivo
2013
·
C Hung
, Y Kuo
, et al.
·
Medical Physics
Multifunctional Molecular Probes for Targeting and Imaging of Epidermal Growth Factor Receptor
2012
·
C. Hung
, Y. Kuo
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Theranostic Nanoprobes for Targeting and Imaging of the Epidermal Growth Factor Receptor
2011
·
C. Hung
, Y. Kuo
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Molecular Probes for Targeting and Imaging of the Epidermal Growth Factor Receptor
2010
·
C. Hung
, Y. Kuo
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Show more works
View as search
Works count:
25
Citation count:
158
H-index:
5
I10-index:
3
Year
Topic
Type